Bank of America Merrill Lynch Form 38.5 (b) - Allergan (6016A)
22 January 2020 - 10:20PM
UK Regulatory
TIDM0Y7T
RNS Number : 6016A
Bank of America Merrill Lynch
22 January 2020
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT,
1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED
INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader Bank of America, N.A., Proprietary
Company dealt in Allergan PLC
-----------------------------------
Class of relevant security to which the Common - IE00BY9D5467
dealings being disclosed relate(Note 1)
-----------------------------------
Date of dealing 21/01/2020
-----------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing)
in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common IE00BY9D5467
Long Short
------------------- -------------------
Number % Number %
---------- ------- ---------- -------
(1) Relevant securities 3,532,969 1.076% 0 0 %
---------- ------- ---------- -------
(2) Derivatives (other than options): 1,786,127 0.544% 5,012,097 1.526%
---------- ------- ---------- -------
(3) Options and agreements to purchase/sell: 0 0% 0 0%
---------- ------- ---------- -------
Total 5,319,096 1.62% 5,012,097 1.526%
---------- ------- ---------- -------
(b) Interests and short positions in relevant securities
of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long Short
------------ ------------
Number % Number %
------- --- ------- ---
(1) Relevant securities 0 0% 0 0%
------- --- ------- ---
(2) Derivatives (other than options): 0 0% 0 0%
------- --- ------- ---
(3) Options and agreements to purchase/sell: 0 0% 0 0%
------- --- ------- ---
Total 0 0% 0 0%
------- --- ------- ---
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 1,161 192.58 USD
------------------------------ ------------------------
Purchase 698 192.633 USD
------------------------------ ------------------------
Purchase 806 192.68 USD
------------------------------ ------------------------
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 806 192.68 USD
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 5) (Note 6) (Note 4)
Swaps Reducing a Long Position 388 192.68 USD
---------------------------- ------------------------------ ---------------
Swaps Reducing a Long Position 59 192.68 USD
---------------------------- ------------------------------ ---------------
Swaps Reducing a Long Position 50 192.68 USD
---------------------------- ------------------------------ ---------------
Swaps Reducing a Long Position 124 192.68 USD
---------------------------- ------------------------------ ---------------
Swaps Increasing a Short Position 659 192.636 USD
---------------------------- ------------------------------ ---------------
Swaps Increasing a Short Position 39 192.636 USD
---------------------------- ------------------------------ ---------------
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry date Option money paid/ received
name, selling, securities price e.g. American, per unit (Note 4)
e.g. call purchasing, to which European
option varying the option etc
etc. relates (Note
7)
N/A N/A N/A N/A N/A N/A N/A
------------- --------------- --------- ---------------- ------------ ------------------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 4)
N/A N/A N/A
---------------------- --------------------
(d) Other dealings (including transactions in respect
of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7) (if applicable) (Note 4)
N/A N/A N/A
--------- ---------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 22/01/2020
Contact name Tolu Tade
------------------------
Telephone number +44207 996 3410
------------------------
Name of offeree/offeror with which connected AbbVie Inc
------------------------
Nature of connection (Note 9) Advisor to - AbbVie Inc
------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISESEUFFEESSEFF
(END) Dow Jones Newswires
January 22, 2020 06:20 ET (11:20 GMT)
Allergan (LSE:0Y7T)
Historical Stock Chart
From Apr 2024 to May 2024
Allergan (LSE:0Y7T)
Historical Stock Chart
From May 2023 to May 2024
